1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 15,200 | 17,200 | 04.07. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| Di | ASCENTAGE (06855): FURTHER GRANT OF AWARDS UNDER THE 2021 RSU SCHEME AND THE 2022 RSU SCHEME; AND FURTHER GRANT OF OPTIONS UNDER THE POST IPO SHARE OPTION ... | 1 | HKEx | ||
| 15.06. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress | 2 | GlobeNewswire (USA) | ||
| ASCENTAGE PHARMA GROUP INTERNATIONAL ADR Aktie jetzt für 0€ handeln | |||||
| 15.06. | ASCENTAGE (06855): VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA RELEASES MULTIPLE CLINICAL UPDATES AT EHA2026 CONGRESS | 2 | HKEx | ||
| 10.06. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 10.06. | ASCENTAGE (06855): VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES BY THE TRUSTEE FOR THE PURPOSE OF THE 2022 RSU SCHEME | - | HKEx | ||
| 10.06. | B.Riley initiates Ascentage Pharma stock with buy, $45 target | 1 | Investing.com | ||
| 01.06. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 01.06. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026 | 2 | GlobeNewswire (USA) | ||
| 01.06. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026 | 1 | GlobeNewswire (USA) | ||
| 01.06. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026 | 1 | GlobeNewswire (USA) | ||
| 27.05. | ASCENTAGE-B (06855): VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES BY THE TRUSTEE FOR THE PURPOSE OF THE 2022 RSU SCHEME | - | HKEx | ||
| 27.05. | ASCENTAGE-B (06855): DIS-APPLICATION OF RULES 18A.09 TO 18A.11 OF THE LISTING RULES AND REMOVAL OF STOCK MARKER | - | HKEx | ||
| 22.05. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 22.05. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026 | 211 | GlobeNewswire (Europe) | ROCKVILLE, Md. and SUZHOU, China, May 21, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company... ► Artikel lesen | |
| 22.05. | ASCENTAGE-B (06855): VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA RELEASES LATEST CLINICAL DATA FROM MULTIPLE TRIALS AT ASCO 2026 | 1 | HKEx | ||
| 21.05. | ASCENTAGE-B (06855): THIRD AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 20.05. | ASCENTAGE-B (06855): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 20, 2026 | 1 | HKEx | ||
| 18.05. | TGI Solar Power Group, Inc.: TGI Solar Power Group CEO Samuel Epstein Elected Secretary/Editor of AAPG House of Delegates; Company Accelerates AXINOD Sovereign AI Strategy | 414 | ACCESS Newswire | Company Concurrently Signals Expansion into High-Growth Sovereign AI Market with AXINOD Modular Infrastructure Strategy MIAMI, FL / ACCESS Newswire / May 18, 2026 / TGI SOLAR POWER GROUP INC. (OTC Markets:TSPG)... ► Artikel lesen | |
| 14.05. | Ascentage Pharma: Interview With Co-Founder & CEO Dr. Dajun Yang About The Global Hematology-Oncology Company | 4 | pulse2.com |
1 2 3 4 Weiter >>
71 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 84,30 | -0,18 % | Novo Nordisk sucht Volumen, BioNTech sucht Beweise | Pharmaaktien werden derzeit nicht einheitlich bewertet. Der Markt unterscheidet härter zwischen bereits kommerzialisierten Blockbustern, deren Preise unter Druck geraten, und Biotech-Pipelines, die... ► Artikel lesen | |
| OCUGEN | 1,342 | -0,15 % | Ocugen Provides Business Update with First Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p About 20%... ► Artikel lesen | |
| VIKING THERAPEUTICS | 32,550 | -0,31 % | Is Viking Therapeutics Stock Going to $50? Here's What the Bulls and Bears Are Saying | ||
| INFLARX | 2,028 | -2,31 % | InflaRx N.V.: InflaRx Assessing Feasibility of Broadened Strategy for ANCA-Associated Vasculitis in Europe Following EMA Recommendation on Tavneos | InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV)The Company is assessing the most efficient... ► Artikel lesen | |
| EDITAS MEDICINE | 3,120 | -1,89 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 16,760 | -0,24 % | Regulatory tracker: FDA sets decision date for Sarepta's DMD drugs | ||
| CARDIOL THERAPEUTICS | 0,930 | 0,00 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders | TORONTO, June 25, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing... ► Artikel lesen | |
| BASILEA | 59,00 | +0,17 % | David Veitch, CEO Basilea, im Interview | von Robert Jakob Moneycab.com: Herr Veitch, Basilea's Cresemba, ein Arzneimittel gegen Sporenpilze, macht mittlerweile weltweit rund 750 Millionen Dollar Umsatz. Wieviel davon schlägt auf die bottom... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 73,88 | +0,65 % | Chardan: Arrowhead Pharmaceuticals ist Top-Pick im Biotech-Sektor vor wichtigen Daten | ||
| TELIX PHARMACEUTICALS | 10,382 | +2,02 % | TELIX PHARMACEUTICALS LIMITED: Ceasing to be a substantial holder | ||
| TWIST BIOSCIENCE | 86,88 | -0,41 % | Cathie Wood's ARK sells Twist Bioscience, buys Circle Internet stock | ||
| ONCO-INNOVATIONS | 0,441 | -1,34 % | Onco-Innovations leitet Studien zur Verstoffwechselung von ONC010 in Hepatozyten und Lebermikrosomen aus drei Tierarten ein | Vancouver, Kanada - 26. Juni 2026 / IRW-Press / Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (FWB: W1H, WKN: A3EKSZ) ("Onco" oder das "Unternehmen") kündigt die Einleitung von Studien... ► Artikel lesen | |
| REPLIGEN | 121,45 | -2,41 % | BioLife is said to have drawn takeover interest from Repligen | ||
| REVOLUTION MEDICINES | 168,25 | +0,72 % | +422% in einem Jahr: Revolution Medicines nach Bauchspeicheldrüsenkrebs-Durchbruch nicht zu ... | Die Rekordfahrt bei der Aktie von Revolution Medicines hat sich zu Wochenbeginn fortgesetzt. Erstmals in der Börsengeschichte der Biotech-Gesellschaft ist der Börsenwert auf über 40 Milliarden Dollar... ► Artikel lesen | |
| UNIQURE | 37,300 | +0,67 % | uniQure (QURE) Now Trades Above Golden Cross: Time to Buy? |
Das Unternehmen ASCENTAGE PHARMA GROUP INTERNATIONAL ADR kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 13,200 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ASCENTAGE PHARMA GROUP INTERNATIONAL ADR finden Sie auf Wallstreet Online.